Group 1 - The core viewpoint of the article indicates a decline in the stock prices of Kingsoft-related companies, specifically Kingsoft Cloud and Kingsoft Software [1] - As of the report, Kingsoft Cloud (03896.HK) has dropped by 7.59% [1] - Kingsoft Software (03888.HK) has also experienced a decline, falling by 7.49% [1]

Group 1 - The Hong Kong stock market showed mixed performance, with the Hang Seng Index down 0.02% and the Hang Seng Tech Index up 0.19% [1] - The Hong Kong Innovative Drug ETF (159567) increased by 0.39%, with a turnover rate of 4.08% and a trading volume exceeding 660 million yuan, indicating active trading [1] - Notable stocks within the ETF included WuXi AppTec, which rose over 5%, WuXi Biologics, which increased over 4%, and Kelun Pharmaceutical, which gained over 2% [1] Group 2 - The innovative drug and AI medical sectors performed actively in Q1, with related fund products showing impressive returns, as the top-performing ETFs have all exceeded a 32% increase year-to-date [1] - The majority of pharmaceutical-themed funds have also shown positive growth, with 90% reporting positive performance for the year [1] - Industry analysts from Industrial Securities expect a steady recovery in the pharmaceutical sector due to favorable policies, particularly in the hospital market, which was previously impacted by anti-corruption and centralized procurement [1] Group 3 - Minsheng Securities highlighted continuous catalysts in the innovative drug sector, focusing on areas such as anti-tumor, autoimmune, GLP-1, stem cell, and gene therapy, while also emphasizing the importance of domestic substitution and medical consumption, particularly in the beauty sector [2]

从一季度财报来看，宝尊电商在营收增长4.3%的同时仍未摆脱亏损，且近年来公司股东不断退场，也 部分反映了市场对于公司的悲观态度。 公开资料显示，2024年5月阿里出售宝尊电商14.4%股权，退出公司股东行列，而在此之前，公司曾经 的股东中JPMorgan Chase & Co.(摩根大通)、Morgan Stanley(摩根士丹利)、软银的Tsubasa Corporation等 知名机构也均已陆续退场。 股价、业绩双双承压，宝尊电商-W(09991)最近的情势不太乐观。5月26日，公司股价收于7.88港元，较 两周前的阶段性高点9.8港元已下滑约20%。 业绩展现颓势，又无资本加持，困境中的宝尊电商将如何重拾投资者的信心? 亏损小幅收窄 销售费用增长较快 财务数据显示，2025年第一季度宝尊电商取得总净营收20.64亿元(人民币，下同)，同比增长4.27%;归属 于该公司普通股股东的净损失6308万元，同比收窄5.34%。这是自2021年第三季度以来，宝尊电商连续 第15个季度处于亏损之中。 电商板块仍然为公司的核心业务，一季度净收入达到17亿元，收入占比为83%。其中，产品销售收入 4.2亿元，同比增长7 ...

Core Viewpoint - The Hong Kong pharmaceutical outsourcing sector is experiencing a strong performance, with notable increases in stock prices for several key companies [1] Company Performance - WuXi Biologics (02269.HK) has seen a stock price increase of 4.70% [1] - Kelun Pharmaceutical (06821.HK) has risen by 4.62% [1] - Tigermed (03347.HK) has gained 1.89% [1] - WuXi AppTec (02359.HK) has increased by 1.36% [1]

营销服务业务方面，公司表示已将低质营销内容消耗量收敛至极低水平，后续将探索AI驱动的营销产 品创新，提升广告主效率与品牌可信度。该行预计2Q25将在这一基础上进行过渡，下半年或有望看到 营销升级成效，关注CCS迭代表现。付费会员方面，内容策略转向"精品短内容+中长篇内容"。职业培 训业务方面，公司表示将推动开发"内容+社群+实践"的融合产品，提升单用户价值;将有制约地投入AI 与社区结合场景。 智通财经APP获悉，中金发布研报称，维持知乎-W(02390)收入预期。考虑到公司费用控制水平，维持 2026年经调整净利润1.36亿元不变。当前股价对应0.8/0.7倍P/S。维持跑赢行业评级及目标价16港元/6.1 美元，均对应1.25倍2025年目标P/S，港/美股上行空间分别为57%/52.5%。 中金主要观点如下： 1Q25业绩好于该行预期 公司1Q25收入7.30亿元，基本符合该行预期7.19亿元;经调整净利润694万元，好于该行预期。该行认为 主要由于：成本及费用控制好于预期，尤其是销售、管理费用。公司宣布将开启新一期回购计划(至 2026年6月25日到期)，最多可回购已发行股份的10%。前一期计划于20 ...

近期，为落实《国务院办公厅关于推动公立医院高质量发展的意见》要求，指导医院科学、规范开展智 慧医疗、智慧服务、智慧管理"三位一体"的智慧医院建设，国家卫生健康委医政司组织对2018年出台的 《电子病历系统应用水平分级评价标准(试行)》进行修订，起草了《智慧医疗分级评价方法及标准(2025 版)》。 新纽科技有限公司(9600.HK，以下简称"新纽科技"或"集团")作为国内较早凭借人工智能、大数据分析 等为代表的创新技术积极助力我国医疗行业数字化转型的科技驱动型IT解决方案服务商，多年来持续向 医疗行业客户提供可助力其改善医疗质量水平、提升内部管理效率的医疗质量控制与安全预警平台、医 疗病历质量综合管理平台、医疗文书数据结构化与管理平台、临床路径监控管理平台等多款创新型IT解 决方案及产品。同时，伴随着我国医院等级评审、DRG/DIP支付方式改革等医疗政策的陆续公布与实 施，新纽科技持续开展对新产品、新技术应用的研发及创新，推动创新技术在病历质量控制与管理方面 的进一步融合与产品迭代更新。 目前，集团旗下病历质控相关产品和解决方案已顺利在多维数据分析、自然语言处理(NLP)、人工智能 等创新技术应用的基础上，引 ...

港股苹果概念股走强，高伟电子(01415.HK)涨近6%、瑞声科技(02018.HK)涨4.47%、舜宇光学科技 (02382.HK)、丘钛科技(01478.HK)涨3.51%。 ...

公司加强员工团队建设以提高员工凝聚力，短期经营利润率承压，长期利于顾客粘性提高。 投资要点： 机构：国泰海通证券 研究员：刘越男/宋小寒 本报告导读： 投资建议：维持增持评级。预测 2025-2027 年收入分别为8.97/11.01/13.41 亿美元，归母净利润分别为 0.43/0.58/0.77 亿美元。 考虑公司海外扩张成长性强，给予2025 年高于行业平均的1.8 倍PS，目标价19.45 港元（按1 美元=7.83 港元折算），维持增持评级。 风险提示：海外门店拓展受阻，海外消费需求疲软，关税提高。 翻台同比提升，聚焦餐厅管理。①门店数：2025Q1 新开4 家，关闭3 家，净增1 家。截至2025Q1 门店 数123 家/同比+3.4%。②同店销售额：2025Q1 同店销售同比+0.3%，其中东南亚同比-2.8%，东亚同比 +14.7%，北美同比+0.8%，其他同比-1.5%。③同店翻台率：2025Q1同店平均翻台率4.0 次/天，同比 +0.1 次；其中东南亚3.8 次/同比持平，东亚4.9 次/同比+0.6 次，北美4.0 次/同比-0.1 次，其他4.0 次/同 比+0.2 次。④人均消费 ...

Core Viewpoint - Innovent Biologics has initiated a Phase 3 clinical study for picankibart, targeting psoriasis patients who have not responded adequately to anti-IL-17 treatments, aiming to provide robust clinical evidence for biologic switching strategies in psoriasis treatment [1][4][6]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focused on developing high-quality medicines for various diseases, including oncologic, autoimmune, cardiovascular, and metabolic conditions [10]. - The company has launched 15 products and has multiple assets in various stages of clinical trials, including 3 new drug applications under regulatory review [10]. Clinical Study Details - The Phase 3 study (NCT06945107) will enroll approximately 310 participants, randomized in a 1:1 ratio to receive either picankibart or continued IL-17 monoclonal antibody treatment [2]. - The primary endpoint is the proportion of participants achieving a static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1) at week 16 [2]. Efficacy and Safety - Previous Phase 2 studies indicated that switching to picankibart resulted in a rapid clinical response, with 64.6% of patients achieving skin lesion clearance after 16 weeks [3][6]. - Nearly half (48.2%) of participants in the Phase 2 study reached the primary endpoint, with a stable response rate of 54.2% through week 44 [5]. Psoriasis Background - Psoriasis is a chronic inflammatory disease affecting 80%-90% of patients with plaque psoriasis, with nearly 30% classified as moderate-to-severe [7]. - Current systemic treatments include various agents, with biologics becoming a central focus since 2019 due to their efficacy and safety [7]. Picankibart Overview - Picankibart (IBI112) is a monoclonal antibody developed by Innovent, targeting the IL-23p19 subunit, which may offer a more effective treatment option for psoriasis and other autoimmune diseases [8]. - The first new drug application for picankibart for moderate-to-severe plaque psoriasis was submitted for review by the NMPA in September 2024 [9].

港股苹果概念股走强 高伟电子涨近6% 智通财经5月29日电，截至发稿，高伟电子(01415.HK)涨5.67%、瑞声科技(02018.HK)涨4.47%、舜宇光 学(02382.HK)涨3.63%、丘钛科技(01478.HK)涨3.51%。 ...